

Gary M. Nath (DC, NJ)*
 Ross A. Epstein (CA)
 Gregory B. Kang (DC, NJ)*
 Joshua B. Goldberg (VA)*
 Viviana Amzel, Ph.D. (DC, PA)
 Robert P. Cogan (CA, DC)

Harold L. Novick (DC, MD)***

Marvin C. Berkowitz (DC, GA)*, Deceased
 September 4, 2004

Irvin A. Lavine (DC)*, Retired
 Donald M. Sandler (MD)*, Retired
 Patent, Trademark and Copyright Causes
 Unfair Competition, Trade Secrets,
 Licensing and Litigation

NATH & ASSOCIATES LLP.

Attorneys at Law
 12264 El Camino Real
 Suite 400
 San Diego, CA 92130

TELEPHONE (858) 792-8211
 FACSIMILE (858) 792-8946

E-MAIL: VAmzel@NATHLAW.COM
 WEB: WWW.NATHLAW.COM

Lee C. Helman (CA)
 Jerald L. Meyer (VA)*
 Tanya E. Harkins (MD)*
 Sheldon M. McGee (DC)*
 Derek Richmond (VA)*
 H. David Starr (DC, MD)*
 Teresa M. Arroyo (MD)*
 Stanley N. Proitgal (DC)
 Susanne M. Hopkins (VA)*
 Alvin E. Tanenholtz **
 Jeremy D. Peterson **

*Practice limited to Matters and Proceedings
 before Federal Courts and Agencies; not Admitted
 in CA

** Registered Patent Agent; not Admitted in CA
 ++ Of Counsel

Please enter 92

FAX COVER SHEET

Examiner:	Iqbal Chowdhury	Company:	US PTO	Fax No:	571-273-8137
From:	Viviana Amzel	Date:	April 12, 2006	Time:	
Direct Dial:	858-792-8211 x-5026	E-Mail:	vamzel@nathlaw.com		
Pages:	3	Ref No.:			

COMMENTS

Dear Iqbal

Attached are the amended claims as per yesterday's telephone interview. They are accepted.
 Please proceed with the allowance of this application. Thank you. Viviana

CONFIDENTIALITY NOTICE

The information in this fax transmission and the documents accompanying it contain confidential information belonging to the sender that is legally privileged. The information is intended only for the use of the individuals or entities named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone to arrange for return of the original documents to us.

CLAIMS

1. (Currently Amended) An isolated ~~natural or synthetic~~ polynucleotide characterized in that it comprising es at least the ~~[[three]]~~ open reading frame ~~s corresponding to~~ the sequences SEQ ID No.1, SEQ ID No.2 and of SEQ ID No.3.

Claims 2 to 5 (Canceled)

6. (Currently Amended) A vector, comprising ~~characterized in that it comprises~~ one of the polynucleotide ~~[[s]]~~ as claimed in claim 1.

7. (Currently Amended) The vector as claimed in claim 6, characterized in that it is a plasmid, a cosmid, a bacterial artificial chromosome (BAC), an integrative element of actinobacteria, a virus or ~~[[else]]~~ a bacteriophage.

Claims 8 and 9 (Canceled)

10. (Currently Amended) An isolated ~~natural or synthetic~~ polypeptide characterized in that it comprises ~~at least any one of the sequences~~ SEQ ID No.2 ~~7 to SEQ ID~~ No.10.

Claim 11 (Canceled)

12. (Currently Amended) An isolated ~~natural or synthetic~~ polypeptide characterized in that it is encoded by [one of] the polynucleotide ~~[[s]]~~ as claimed in claim 1 or one of the ~~a~~ vector ~~[[s]]~~ comprising said polynucleotide.

USSN 10/518,019
Attorney No. 26438U

13. (Currently Amended) A method for producing a polypeptide, comprising expressing the use of a the polynucleotide as claimed in of claim 1 or of a vector comprising said polynucleotide under effective conditions ,for preparing a polypeptide.

Claim 14 (Canceled)

15. (Currently Amended) A method for preparing a biological system, comprising transfecting the The use of at least one polynucleotide as claimed in of claim 1 or of a vector comprising said polynucleotide into a microorganism, and allowing the expression of the polynucleotide, for preparing an modified biological system or a modified in vitro acellular system.

16. (Currently Amended) A method for expressing a polynucleotide, comprising transfecting the polynucleotide of claim 1 or a vector comprising said polynucleotide into The use as claimed in claim 15, characterized in that the modified biological system is a microorganism or an isolated heterologous host cell selected from expression system using prokaryotic [[es]] or eukaryotic cells [[es]], and allowing the expression of the polynucleotide as hosts.

17. (Currently Amended) An isolated modified biological system, comprising characterized in that it contains at least one of the polynucleotide [[s]] as described in claim 1 [[and/]] or at least one [[of the]] vector comprising said polynucleotide [[s]].

18. (Currently Amended) The biological system as claimed in claim 17, further comprising characterized in that it consists of a microorganism, or a heterologous expression

USSN 10/518,019
Attorney No. 26438U

system comprising an isolated host cell selected from a ~~using~~ prokaryotic ~~[[es]]~~ or eukaryotic ~~[[es-as]]~~ host cell, or ~~else an in-vitro~~ a cell-free translation acellular system.

19. (Currently Amended) The biological system as claimed in claim 18, characterized in that the microorganism is a bacterium selected from ~~such as~~ *Escherichia coli* or *Streptomyces lividans*.

20. (Currently Amended) A cell free translation ~~modified in-vitro~~ acellular system, comprising ~~characterized in that it contains at least one of the polynucleotide of~~ ~~s as described in~~ claim 1 ~~[[and/]]~~ or a ~~least one of the~~ vector ~~[[s]]~~ comprising said polynucleotide.

Claims 21 to 31 (Canceled)